General characteristics of cohort.
| Characteristics | Values |
|---|---|
| Patients, n | 499 |
| Age, yrs, mean (SD) | 57.2 (29.3) |
| Male/female, % | 17.1/82.9 |
| Diagnosis, n (%) | |
| Rheumatoid arthritis | 361 (72.3) |
| Axial spondyloarthritis | 101 (20.2) |
| Psoriatic arthritis | 30 (6) |
| JIA | 7 (1.4) |
| Antibody status, % | |
| RA with RF- or ACPA-positive | 63.7 |
| ANA in cohort | 6.3 |
| Disease duration, yrs, mean (SD) | 15.8 (11.2) |
| Prior no. biologics, IV or SC, mean (95% CI) | 1.8 (1.6–2.3) |
| Concomitant therapy, overall/RA patients, n (%) | |
| Methotrexate | 218 (43.7)/193 (53.4) |
| Other sDMARD | 39 (7.8)/30 (8.8) |
| Corticosteroids | 246 (49.4)/179 (49.5) |
JIA: juvenile idiopathic arthritis; RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; ANA: antinuclear antibody; IV: intravenous; SC: subcutaneous; sDMARD: synthetic disease-modifying antirheumatic drug.